Prognostic and therapeutic implications of TP53 expression in chronic myelomonocytic leukemia

Blood Cancer J. 2024 Jul 12;14(1):112. doi: 10.1038/s41408-024-01087-7.

Yu-Hung Wang^{1

2}, Chien-Chin Lin^{2

3}, Kristian Gurashi¹, Chi-Yuan Yao^{2

3}, Andres Jerez⁴, Hsin-An Hou², Wen-Chien Chou^{2

3}, Hwei-Fang Tien^{2

5}, Kiran Batta⁶, Daniel H Wiseman⁷

¹ Division of Cancer Sciences, Epigenetics of Haematopoiesis Laboratory, The University of Manchester, Manchester, UK.
² Division of Hematology, National Taiwan University Hospital, Taipei, Taiwan.
³ Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan.
⁴ Haematology Department, Hospital Morales Meseguer, Murcia, Spain.
⁵ Department of Internal Medicine, Far-Eastern Memorial Hospital, New Taipei City, Taiwan.
⁶ Division of Cancer Sciences, Epigenetics of Haematopoiesis Laboratory, The University of Manchester, Manchester, UK. kiran.batta@manchester.ac.uk.
⁷ Division of Cancer Sciences, Epigenetics of Haematopoiesis Laboratory, The University of Manchester, Manchester, UK. daniel.wiseman@manchester.ac.uk.

No abstract available

Publication types